Next Science (ASX:NXS) FCF Margin % : -63.07% (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Next Science FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Next Science's Free Cash Flow for the six months ended in Dec. 2023 was A$-11.37 Mil. Next Science's Revenue for the six months ended in Dec. 2023 was A$18.03 Mil. Therefore, Next Science's FCF Margin % for the quarter that ended in Dec. 2023 was -63.07%.

As of today, Next Science's current FCF Yield % is -30.77%.

The historical rank and industry rank for Next Science's FCF Margin % or its related term are showing as below:

ASX:NXS' s FCF Margin % Range Over the Past 10 Years
Min: -365.95 Med: -104.72 Max: -71.87
Current: -71.87

During the past 6 years, the highest FCF Margin % of Next Science was -71.87%. The lowest was -365.95%. And the median was -104.72%.

ASX:NXS's FCF Margin % is ranked worse than
87.29% of 1023 companies
in the Drug Manufacturers industry
Industry Median: 0.29 vs ASX:NXS: -71.87

Next Science FCF Margin % Historical Data

The historical data trend for Next Science's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Next Science FCF Margin % Chart

Next Science Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-343.24

-365.95

-100.37

-104.72

-71.88

Next Science Semi-Annual Data
	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Margin %	Get a 7-Day Free Trial					-109.18	-120.06	-91.54	-82.40	-63.07

Competitive Comparison of Next Science's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, Next Science's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Next Science's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Next Science's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Next Science's FCF Margin % falls into.

Next Science FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Next Science's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-23.819	/	33.135
	=	-71.88 %

Next Science's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-11.371	/	18.028
	=	-63.07 %

Next Science FCF Margin % Related Terms

Thank you for viewing the detailed overview of Next Science's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Next Science (ASX:NXS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Next Science Ltd (ASX:NXS) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

NXSCF:USA

Address

821 Pacific Highway, Suite 1902, Level 19, Tower A, The Zenith Building, Chatswood, NSW, AUS, 2067

Website

https://www.nextscience.com

Next Science Ltd is a medical technology company. It is engaged in the development and commercialization of its proprietary Xbio technology to reduce the impact of biofilm-based infections in human health. Xbio is a non-toxic technology with proven efficacy in eradicating both biofilm based and free-floating bacteria. Its products include Bactisure, SURGX, XEPERIENCE and BLASTX. The company derives revenue from the U.S. and Australia, of which prime revenue is derived from the U.S.

Next Science (ASX:NXS) Headlines

No Headlines